BiotechTube

EBR/GZR

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Human Immunodeficiency Virus

Conditions

Human Immunodeficiency Virus, Hepatitis C

Trial Timeline

Aug 28, 2017 → Nov 30, 2018

NCT ID
NCT03221582

About EBR/GZR

EBR/GZR is a approved stage product being developed by Merck for Human Immunodeficiency Virus. The current trial status is terminated. This product is registered under clinical trial identifier NCT03221582. Target conditions include Human Immunodeficiency Virus, Hepatitis C.

What happened to similar drugs?

13 of 20 similar drugs in Human Immunodeficiency Virus were approved

Approved (13) Terminated (3) Active (7)
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved
✅GardasilMerckApproved
✅RaltegravirMerckApproved
✅RaltegravirMerckApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03420300ApprovedCompleted
NCT03221582ApprovedTerminated

Competing Products

20 competing products in Human Immunodeficiency Virus

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
19
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
40
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
dolutegravirShionogiPhase 3
40
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
40
GSK1349572 + EfavirenzShionogiPhase 1
29
GSK1349572ShionogiPhase 1
29
GSK1349572 + PlaceboShionogiPhase 2
35
Dolutegravir + MethadoneShionogiPhase 1
29
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir PlaceboShionogiPhase 3
40
GSK1349572 + Rifampin + RifabutinShionogiPhase 1
29
DTG + BCV + TVRShionogiPhase 1
29